Deleted Journal, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 30, 2024
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Aug. 28, 2024
Abstract Hyperuricemia, characterized by elevated levels of serum uric acid (SUA), is linked to a spectrum commodities such as gout, cardiovascular diseases, renal disorders, metabolic syndrome, and diabetes, etc. Significantly impairing the quality life for those affected, prevalence hyperuricemia an upward trend globally, especially in most developed countries. UA possesses multifaceted role, antioxidant, pro-oxidative, pro-inflammatory, nitric oxide modulating, anti-aging, immune effects, which are significant both physiological pathological contexts. The equilibrium circulating urate hinges on interplay between production excretion, delicate balance orchestrated transporter functions across various epithelial tissues cell types. While existing research has identified involvement numerous biological processes signaling pathways, precise mechanisms connecting disease etiology remain be fully elucidated. In addition, influence genetic susceptibilities environmental determinants calls detailed nuanced examination. This review compiles data from global epidemiological studies clinical practices, exploring foundations transporters depth. Furthermore, we uncover complex induced inflammation influences individuals with association its relative disease, offering foundation innovative therapeutic approaches advanced pharmacological strategies.
Language: Английский
Citations
75
Drugs, Journal Year: 2023, Volume and Issue: 83(16), P. 1501 - 1521
Published: Oct. 11, 2023
Language: Английский
Citations
32
Nature Reviews Rheumatology, Journal Year: 2024, Volume and Issue: 20(4), P. 216 - 231
Published: March 12, 2024
Language: Английский
Citations
13
Diabetology & Metabolic Syndrome, Journal Year: 2024, Volume and Issue: 16(1)
Published: May 12, 2024
Diabetes mellitus is one of the most significant global burden diseases. It well established that a chronic, systemic, low-grade inflammatory condition strongly correlated with type 2 diabetes (T2D) and development target-organ damage (TOD). Sodium-glucose cotransporter inhibitors (SGLTis), novel oral drugs for treatment diabetes, act mainly by reducing glucose reabsorption in proximal renal tubules and/or intestine. Several high-quality clinical trials large observational studies have revealed SGLTis significantly improve cardiovascular outcomes T2D patients. Increasing evidence suggests this closely related to their anti-inflammatory properties, which are manifested reduction plasma concentrations biomarkers. This review analyses potential mechanisms behind effects presents recent therapeutic efficacy treating TOD.
Language: Английский
Citations
10
Biosensors and Bioelectronics, Journal Year: 2024, Volume and Issue: 261, P. 116509 - 116509
Published: June 20, 2024
Language: Английский
Citations
8
BMJ, Journal Year: 2024, Volume and Issue: unknown, P. e080035 - e080035
Published: Oct. 30, 2024
To emulate target trials comparing recurrence of nephrolithiasis among patients with pre-existing (overall and stratified by concomitant gout) initiating sodium-glucose cotransporter-2 (SGLT-2) inhibitors versus an active comparator.
Language: Английский
Citations
6
Current Hypertension Reports, Journal Year: 2024, Volume and Issue: 26(12), P. 463 - 474
Published: June 24, 2024
Purpose of Review Chronic kidney disease and end-stage (ESKD) are well-established risk factors for cardiovascular (CVD), the leading cause mortality in dialysis population. Conventional therapies, such as statins, blood pressure control, renin-angiotensin-aldosterone system blockade, have inadequately addressed this risk, highlighting unmet need effective treatment strategies. Sodium–glucose transporter 2 (SGLT2) inhibitors demonstrated significant renal benefits among patients with type diabetes, heart failure, or CKD at progression. Unfortunately, efficacy data is lacking ESKD was an exclusion criterion all major clinical trials SGLT2 inhibitors. This review explores potential improving outcomes ESKD, focusing on their direct cardiac effects. Recent Findings preclinical studies shown promising application to may provide patients, not only indirectly by preserving remaining function anemia but also directly lowering intracellular sodium calcium levels, reducing inflammation, regulating autophagy, alleviating oxidative stress endoplasmic reticulum within cardiomyocytes endothelial cells. Summary examines current evidence experimental supporting use inhibitors, discusses its safety concerns, outlines ongoing Further research needed evaluate effectiveness inhibitor ESKD.
Language: Английский
Citations
5
Endocrinología Diabetes y Nutrición (English ed ), Journal Year: 2025, Volume and Issue: 72(1), P. 26 - 36
Published: Jan. 1, 2025
Language: Английский
Citations
0
Deleted Journal, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 21, 2025
Citations
0
Annals of Internal Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: March 10, 2025
Gout is characterized by deposition of monosodium urate (MSU) crystals in or around joints, tendons, bursae, and other tissues, resulting painful recurrent flares tissue damage. the most common form inflammatory arthritis, with a prevalence 5.1% United States, affecting 12.1 million adults. When levels exceed limit solubility (6.8 mg/dL [400 μmol/L]), MSU may grow. are result responses to crystals. The primary method prevent reduce gout flares, tophi, chronic joint damage below saturation threshold. pathophysiology well understood, inexpensive effective therapies available. However, outcomes for patients remain poorly optimized.
Language: Английский
Citations
0